$OVID News

Ovid Therapeutics Promotes Charles Carter As CFO Succeeding Jeffrey Rona

Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally

Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics Q1 EPS $(0.12) Misses $(0.11) Estimate

Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks

Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders - Slideshow

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

Ovid Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $2 to $4.

Ovid Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $2 to $4.

HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $4

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

OVID Therapeutics Inc (NASDAQ:OVID) Passes Minervini's High-Growth Momentum and Trend Template Filters

Ovid Therapeutics shares are trading higher after Wedbush mantained its Outperform rating and raises its price target from $5 to $7.

Wedbush Maintains Outperform on Ovid Therapeutics, Raises Price Target to $7

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding